EC Number |
Inhibitors |
Structure |
---|
1.4.3.3 | (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine |
MK-801, a drastic decline in the expression of DAO mRNA is observed in most brain areas 1 h after the MK-801 administration (1.6 mg/kg) |
|
1.4.3.3 | (5R)-4-hydroxy-3,5-dimethyl-5-[(1E)-2-methyl-1,3-butadienyl]-2(5H)-thiophenone |
i.e. thiolactomycin, competitive inhibition, competes with both the substrate and the coenzyme FAD |
|
1.4.3.3 | ([4-[(3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl)amino]-1H-pyrrole-2-carbonyl]amino)acetic acid |
100% inhibition at 0.02 mM |
|
1.4.3.3 | ([4-[(4,5-dibromo-1H-pyrrole-2-carbonyl)amino]-1H-pyrrole-2-carbonyl]amino)acetic acid |
100% inhibition at 0.02 mM |
|
1.4.3.3 | ([4-[(4,5-dichloro-1H-pyrrole-2-carbonyl)amino]-1H-pyrrole-2-carbonyl]amino)acetic acid |
100% inhibition at 0.02 mM |
|
1.4.3.3 | ([4-[(4-bromo-1H-pyrrole-2-carbonyl)amino]-1H-pyrrole-2-carbonyl]amino)acetic acid |
100% inhibition at 0.02 mM |
|
1.4.3.3 | 1,3-Butadien 1-carboxylic acid |
D-phenylglycine oxidation |
|
1.4.3.3 | 1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione |
- |
|
1.4.3.3 | 1,4-dihydropyrrolo[3,2-c]pyrazole-5-carboxylic acid |
- |
|
1.4.3.3 | 1H-indole-2-carboxylic acid |
- |
|